REAL WORLD OUTCOMES IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS WHO ARE IMMUNO-ONCOLOGY (IO) NAIVE AND RECEIVED SECOND-LINE THERAPY: ANALYSIS BY TUMOR MUTATIONAL BURDEN (TMB) STATUS

被引：0
|
作者：
Gogate, A. [1 ]
Palaia, J. [2 ]
Zhang, Y. [2 ]
You, M. [2 ]
Sama, A. [2 ]
机构：
[1] Bristol Myers Squibb, Pennington, NJ USA
[2] Bristol Myers Squibb, Lawrence Township, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD110
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 12 条
  • [1] Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
    Wells, J. Connor
    Dudani, Shaan
    Gan, Chun Loo
    Stukalin, Igor
    Azad, Arun A.
    Liow, Elizabeth
    Donskov, Frede
    Yuasa, Takeshi
    Pal, Sumanta K.
    De Velasco, Guillermo
    Hansen, Aaron R.
    Beuselinck, Benoit
    Kollmannsberger, Christian K.
    Powles, Thomas
    McGregor, Bradley A.
    Duh, Mei S.
    Huynh, Lynn
    Heng, Daniel Y. C.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 354 - 361
  • [2] Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US)
    Boyd, Marley
    Annavarapu, Srinivas
    Doshi, Gurjyot K.
    Imai, Kentaro
    Sbar, Eric
    Godwin, James Luke
    Li, Haojie
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)
    Talbot, D.
    Fish, S. M.
    Ong, T. Jin
    Flick, E. D.
    Waterhouse, D. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Real-world use and clinical impact of electronic patient-reported outcomes (ePROs) in patients with solid tumors treated with immuno-oncology (10) therapy
    Dickson, Natalie R.
    Beauchamp, Karen D.
    Perry, Toni S.
    Roush, Ashley
    Goldschmidt, Deborah
    Edwards, Marie Louise
    Blakely, L. Johnetta
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 416 - 416
  • [5] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Pranav Abraham
    Joe Gricar
    Ying Zhang
    Veena Shankaran
    Advances in Therapy, 2020, 37 : 3392 - 3403
  • [6] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
    Abraham, Pranav
    Gricar, Joe
    Zhang, Ying
    Shankaran, Veena
    ADVANCES IN THERAPY, 2020, 37 (07) : 3392 - 3403
  • [7] Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
    Gutierrez, M. E.
    Norden, A. D.
    Lane, D. C.
    Canavan, B. F.
    Nwokeji, E. D.
    Xu, Y.
    Kaur, S.
    Goldberg, S. L.
    Noh, L.
    Siegartel, L.
    Whittington, J.
    Tuell, K.
    Korytowsky, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 436 - 437
  • [8] Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
    Wang, C. K.
    Gupte-Singh, K.
    Belli, A. J.
    Lane, D. C.
    Lakshmanan, A.
    Norden, A. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
    Ajmera, M.
    Chang, J.
    Hitchens, A.
    Kearney, M.
    Esterberg, E.
    Kim, R.
    Cappelleri, J.
    Devgan, G.
    Costa, N.
    Candrilli, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S715 - S716
  • [10] Contemporary real-world treatment patterns and outcomes of patients with advanced/metastatic hepatocellular carcinoma receiving second-line systemic therapy in the United States.
    Gupta, Arjun
    Girvan, Allicia C.
    Sheffield, Kristin M.
    Chen Yongmei
    Kirsch, Kelly Rae
    Gugel, Elena Gonzalez
    Peachey, Jessica
    Cui, Zhanglin Lin
    Yarchoan, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12